Published in Semin Immunopathol on October 27, 2016
Role of liver ICAM-1 in metastasis. Oncol Lett (2017) 0.75
Cancer and autoimmunity. Semin Immunopathol (2017) 0.75
STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer (2009) 15.45
Exosomes: composition, biogenesis and function. Nat Rev Immunol (2002) 13.99
Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12.19
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med (2012) 11.14
The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 10.90
Nitric oxide and the immune response. Nat Immunol (2001) 10.00
Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A (1998) 6.82
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med (2013) 5.82
MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A (2012) 5.07
Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol (2015) 4.25
Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int (2010) 4.13
Tumour exosome integrins determine organotropic metastasis. Nature (2015) 4.09
Protein sorting into multivesicular endosomes. Curr Opin Cell Biol (2003) 4.04
HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med (2010) 4.00
Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res (2011) 3.73
Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med (2002) 3.02
Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother (2010) 3.00
Immune cell regulation by autocrine purinergic signalling. Nat Rev Immunol (2011) 2.94
Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res (2009) 2.90
Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest (2010) 2.89
Humoral immunity, inflammation and cancer. Curr Opin Immunol (2007) 2.68
Chemokines: agents for the immunotherapy of cancer? Nat Rev Immunol (2002) 2.68
Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev (2008) 2.62
PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med (2014) 2.51
The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer (2013) 2.35
Regulatory T cells in cancer immunotherapy. Curr Opin Immunol (2014) 2.32
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer (2014) 2.27
Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res (2011) 2.20
The two faces of interferon-γ in cancer. Clin Cancer Res (2011) 2.20
Tumor-associated neutrophils: friend or foe? Carcinogenesis (2012) 2.15
Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med (2011) 2.06
Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells. J Immunol (2011) 2.05
A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood (2011) 2.03
Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res (2009) 2.02
The amount and proteolytic content of vesicles shed by human cancer cell lines correlates with their in vitro invasiveness. Anticancer Res (1998) 1.94
Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother (2011) 1.94
Communication by Extracellular Vesicles: Where We Are and Where We Need to Go. Cell (2016) 1.93
Transgenic mouse model for skin malignant melanoma. Oncogene (1998) 1.90
Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci U S A (2011) 1.89
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol (2013) 1.86
Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2. Cancer Res (2007) 1.70
Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci (2014) 1.69
Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma. J Invest Dermatol (2012) 1.62
Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients. Cancer Cell (2016) 1.58
Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev (2011) 1.55
Tumor necrosis factor-α blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. Immunity (2013) 1.55
Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin Immunopathol (2013) 1.54
Melanoma miRNA trafficking controls tumour primary niche formation. Nat Cell Biol (2016) 1.49
Recent advances on the role of tumor exosomes in immunosuppression and disease progression. Semin Cancer Biol (2012) 1.46
Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives. Immunol Invest (2012) 1.43
Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells. Clin Cancer Res (2013) 1.43
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun (2016) 1.39
RET proto-oncogene in the development of human cancer. J Clin Oncol (1999) 1.38
An ex(o)citing machinery for invasive tumor growth. Cancer Res (2010) 1.31
Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in ret transgenic mice spontaneously developing melanoma. Clin Cancer Res (2009) 1.28
Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells. Oncogene (2006) 1.27
Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment. Adv Cancer Res (2015) 1.25
Therapeutic cancer vaccines. J Clin Invest (2015) 1.23
Melanoma-induced immunosuppression and its neutralization. Semin Cancer Biol (2012) 1.23
Body fluid exosomes promote secretion of inflammatory cytokines in monocytic cells via Toll-like receptor signaling. J Biol Chem (2013) 1.22
Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PLoS One (2013) 1.22
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Trends Immunol (2016) 1.20
New insights into chronic inflammation-induced immunosuppression. Semin Cancer Biol (2012) 1.19
Generation of anti-inflammatory adenosine by leukocytes is regulated by TGF-β. Eur J Immunol (2011) 1.16
Matrix metalloproteinase 12 overexpression in myeloid lineage cells plays a key role in modulating myelopoiesis, immune suppression, and lung tumorigenesis. Blood (2011) 1.14
On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Sci Transl Med (2015) 1.14
Macrophage immunomodulation by breast cancer-derived exosomes requires Toll-like receptor 2-mediated activation of NF-κB. Sci Rep (2014) 1.10
Interleukin-1α. Semin Immunol (2013) 1.09
Interactions between innate and adaptive lymphocytes. Nat Rev Immunol (2014) 1.08
Melanoma immunology: past, present and future. Curr Opin Oncol (2007) 1.07
Current advances and perspectives in the treatment of advanced melanoma. J Dtsch Dermatol Ges (2012) 1.06
Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists. Cancer Immunol Res (2014) 1.06
Exosomes and tumor-mediated immune suppression. J Clin Invest (2016) 1.06
Extracellular vesicle-mediated transfer of functional RNA in the tumor microenvironment. Oncoimmunology (2015) 1.05
C-C chemokine receptor 5 on stromal cells promotes pulmonary metastasis. Cancer Res (2005) 1.05
Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab. Clin Cancer Res (2015) 1.05
Chemokines and cancer: a fatal attraction. Cancer Cell (2011) 1.05
Melanoma-specific memory T cells are functionally active in Ret transgenic mice without macroscopic tumors. Cancer Res (2008) 1.01
Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs. J Immunol (2009) 1.00
Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model. J Immunol (2013) 1.00
Cyclophosphamide-induced myeloid-derived suppressor cell population is immunosuppressive but not identical to myeloid-derived suppressor cells induced by growing TC-1 tumors. J Immunother (2012) 0.99
MiRNA in melanoma-derived exosomes. Cancer Lett (2014) 0.98
Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production. Cancer Immunol Res (2013) 0.97
Adoptive T-Cell Therapy for Cancer. Adv Immunol (2016) 0.97
Novel insights into exosome-induced, tumor-associated inflammation and immunomodulation. Semin Cancer Biol (2014) 0.96
Tumor Exosomal RNAs Promote Lung Pre-metastatic Niche Formation by Activating Alveolar Epithelial TLR3 to Recruit Neutrophils. Cancer Cell (2016) 0.96
The immune contexture of primary and metastatic human tumours. Curr Opin Immunol (2014) 0.96
Myeloid-derived suppressor cells in malignant melanoma. J Dtsch Dermatol Ges (2014) 0.95
Predominant expression of CCL2 at the tumor site of prostate cancer patients directs a selective loss of immunological tolerance to CCL2 that could be amplified in a beneficial manner. J Immunol (2009) 0.94
New therapeutic options for advanced non-resectable malignant melanoma. Adv Med Sci (2014) 0.94
Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients. Cancer Immunol Immunother (2013) 0.94
Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients. Int J Cancer (2014) 0.93
Exosome-mediated transfer of miR-222 is sufficient to increase tumor malignancy in melanoma. J Transl Med (2016) 0.92
Regulation of the inflammatory profile of stromal cells in human breast cancer: prominent roles for TNF-α and the NF-κB pathway. Stem Cell Res Ther (2015) 0.90
The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible "hard" lesions. Cancer Immunol Immunother (2010) 0.90
Host absence of CCR5 potentiates dendritic cell vaccination. J Immunol (2003) 0.89
Dissecting the autocrine and paracrine roles of the CCR2-CCL2 axis in tumor survival and angiogenesis. PLoS One (2012) 0.89
Tumor-Promoting Effects of Myeloid-Derived Suppressor Cells Are Potentiated by Hypoxia-Induced Expression of miR-210. Cancer Res (2015) 0.86
Chemokines and Chemokine Receptors in Lymphoid Tissue Dynamics. Annu Rev Immunol (2016) 0.83
Paving the Road to Tumor Development and Spreading: Myeloid-Derived Suppressor Cells are Ruling the Fate. Front Immunol (2015) 0.82